27 completed, 11 recruiting, 8 active not recruiting, 7 terminated. 32 Phase 2, 22 Phase 1, 5 Not applicable, 5 Phase 3, 1 Early Phase 1.
Follow Advanced Renal Cell Carcinoma: new trials by email Literature Review of Advanced Renal Cell Carcinoma trials Research Report on Advanced Renal Cell Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Mercaptopurine for the Treatment of Hereditary Leiomyomatosis and Renal Cell Carcinoma (HLRCC), Uterine/Cutaneous Leiomyomas, and Kidney Cancer Biopsy Procedure, Biospecimen Collection, Computed Tomography - Advanced Kidney Carcinoma, Advanced Renal Cell Carcinoma | Phase 1 | Not yet recruiting | Jonsson Comprehensive Cancer Center | 18 | 2026-12-01 | 2026-08-06 |
| RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy Biopsy Procedure, Biospecimen Collection, Computed Tomography - Advanced Clear Cell Renal Cell Carcinoma, Advanced Renal Cell Carcinoma | Phase 2 | Withdrawn | City of Hope Medical Center | 2026-08-11 | 2026-10-01 | |
| Sitagliptin With Pembro in RCC and Melanoma Sitagliptin, Pembrolizumab - Advanced Renal Cell Carcinoma, Advanced Melanoma | Phase 1 | Recruiting | Fernando Maciel Barbosa | 64 | 2026-05-14 | 2026-07-30 |
| Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study Biospecimen Collection, Immune Checkpoint Inhibitor - Advanced Biliary Tract Carcinoma, Advanced Head and Neck Squamous Cell Carcinoma | Phase 4 | Recruiting | OHSU Knight Cancer Institute | 160 | 2026-04-24 | 2026-10-13 |
| Fasting-Mimicking Diet Combined With IO-TKI Combination Therapy in Patients With Metastatic Renal Cell Carcinoma Fasting mimicking diet, Toripalimab, Axitinib - Carcinoma, Renal Cell, Metastatic Renal Cell Carcinoma | Not applicable | Not yet recruiting | Qilu Hospital of Shandong University | 43 | 2026-04-01 | 2026-03-30 |
| Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC XL092, Nivolumab - Advanced Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma | Phase 2 | Recruiting | Karie Runcie | 70 | 2026-03-13 | 2026-09-22 |
| Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer PF-08634404, Ipilimumab, Axitinib - Carcinoma, Renal Cell, Advanced Renal Cell Carcinoma | Phase 1 / Phase 2 | Recruiting | Pfizer | 224 | 2026-02-10 | 2026-10-08 |
| Phase Ib/II Clinical Study of SHR-8068 Combined Anti-tumor Drugs in the Treatment of Advanced Renal Cell Carcinom SHR-8068；Adebrelimab ；Bevacizumab, SHR-8068 ; SHR-4610 - Advanced Renal Cell Carcinoma | Phase 1 / Phase 2 | Recruiting | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 92 | 2026-01-06 | 2026-08-11 |
| Clinical Study of a Novel Humanized CD70-Targeted CAR-T Cell Incorporating TLR2 for Advanced Renal Cell Carcinoma Therapy CAR-T(CD70) - Advanced Renal Cell Carcinoma | Early Phase 1 | Not yet recruiting | Wei Guan | 30 | 2025-08-15 | 2025-08-11 |
| CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer Biospecimen Collection, Bone Scan, CBM588 Capsules - Advanced Clear Cell Renal Cell Carcinoma, Advanced Renal Cell Carcinoma | Phase 1 | Recruiting | Osel, Inc. | 28 | 2024-06-19 | 2024-05-30 |
| Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program Home Health Encounter, Nivolumab, Patient Monitoring - Advanced Esophageal Squamous Cell Carcinoma, Advanced Renal Cell Carcinoma | Phase 2 | Recruiting | Mayo Clinic | 50 | 2024-04-30 | 2026-10-02 |
| Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial Botensilimab, Balstilimab, Ipilimumab - Advanced Renal Cell Carcinoma | Phase 2 | Suspended | Michael B. Atkins, MD | 120 | 2023-09-25 | 2026-02-11 |
| At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer Clinical Encounter, Home Health Encounter, Quality-of-Life Assessment - Advanced Anal Carcinoma, Advanced Biliary Tract Carcinoma | Phase 2 | Recruiting | Mayo Clinic | 220 | 2023-08-23 | 2026-04-20 |
| Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc) NKT2152, palbociclib, sasanlimab - ccRCC, Clear Cell Renal Cell Carcinoma | Phase 2 | Terminated | NiKang Therapeutics, Inc. | 18 | 2023-07-28 | 2025-11-12 |
| The Immune Effects of Fermented Wheat Germ Nutritional Supplementation in Patients With Advanced Solid Tumor Cancers Being Treated With Standard of Care Checkpoint Inhibitors Fermented Wheat Germ Extract - Advanced Colorectal Carcinoma, Advanced Lung Non-Small Cell Carcinoma | Phase 1 | Suspended | University of California, Davis | 100 | 2023-06-02 | 2026-07-01 |
| Combination of 177Lu-TLX250 and Peposertib in Patients With Carbonic Anhydrase IX -Expressing Solid Tumors 89Zr-TLX250, 177Lu-TLX250 and Peposertib - Solid Tumor, Adult, Advanced Solid Tumor | Phase 1 | Recruiting | Telix Pharmaceuticals (Innovations) Pty Limited | 36 | 2023-05-23 | 2024-05-01 |
| Study of CAR.70-engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Advanced Renal Cell Carcinoma, Mesothelioma and Osteosarcoma CAR.70/IL15-transduced CB-derived NK cells, Fludarabine phosphate, Cyclophosphamide - Advanced Renal Cell Carcinoma, Advanced Mesothelioma | Phase 1 / Phase 2 | Suspended | M.D. Anderson Cancer Center | 50 | 2023-03-29 | 2026-07-31 |
| Study of ST-1898 in Advanced Renal Cell Carcinoma ST-1898 tablets - Advanced Renal Cell Carcinoma | Phase 1 / Phase 2 | Active not recruiting | Beijing Scitech-Mq Pharmaceuticals Limited | 90 | 2023-02-07 | 2025-08-24 |
| First-in-human Phase I Study to Evaluate Safety, Tolerability and Antineoplastic Activity of OATD-02 in Patients With Selected Advanced and/or Metastatic Solid Tumours OATD-02 - Advanced Ovarian Carcinoma, Advanced Renal Cell Carcinoma | Phase 1 | Recruiting | Molecure S.A. | 40 | 2023-01-26 | 2026-07-31 |
| Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2) fruquintinib+sintilimab, axitinib / everolimus, fruquintinib - Advanced Renal Cell Carcinoma | Phase 2 / Phase 3 | Completed | Hutchmed | 265 | 2022-10-27 | 2026-10-20 |
Showing 20 of 64. Sign in to see all of them.
Carcinoma, Renal Cell (31) · Kidney Neoplasms (12) · Carcinoma, Non-Small-Cell Lung (5) · Colorectal Neoplasms (5) · Lung Neoplasms (5) · Carcinoma, Hepatocellular (4) · Clear-cell metastatic renal cell carcinoma (4) · Melanoma (4) · Neoplasm Metastasis (4) · Ovarian Neoplasms (4) · Prostatic Neoplasms (4) · Squamous Cell Carcinoma of Head and Neck (3) · Breast Neoplasms (2) · Carcinoma (2) · Carcinoma, Transitional Cell (2)
Neoplasms (38) · Male Urogenital Diseases (36) · Neoplasms by Site (36) · Urogenital Diseases (36) · Female Urogenital Diseases (35) · Female Urogenital Diseases and Pregnancy Complications (35) · Neoplasms by Histologic Type (34) · Urogenital Neoplasms (34) · Kidney Diseases (32) · Neoplasms, Glandular and Epithelial (32) · Urologic Diseases (32) · Urologic Neoplasms (31) · Adenocarcinoma (30) · Carcinoma (30) · Kidney Neoplasms (21)
Nivolumab (11) · Axitinib (7) · Specimen Handling (7) · Ipilimumab (6) · cabozantinib (6) · Magnetic Resonance Spectroscopy (4) · Sorafenib (4) · Sunitinib (4) · pazopanib (3) · tivozanib (3) · trebananib (3) · Biopsy (2) · CTLA-4 Antigen (2) · Disulfides (2) · Home Care Services (2)
Amgen (5) · Ipsen (4) · National Cancer Institute (NCI) (4) · Pfizer (4) · City of Hope Medical Center (3) · M.D. Anderson Cancer Center (3) · AVEO Pharmaceuticals, Inc. (2) · Argos Therapeutics (2) · Mayo Clinic (2) · Michael B. Atkins, MD (2) · NiKang Therapeutics, Inc. (2) · AbbVie (prior sponsor, Abbott) (1) · Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA (1) · Beijing Scitech-Mq Pharmaceuticals Limited (1) · Bristol-Myers Squibb (1)
United States (38) · United Kingdom (9) · France (8) · Spain (7) · Canada (6) · China (6) · Germany (6) · Italy (6) · Australia (5) · Czechia (5) · Hungary (5) · Chile (4) · Japan (4) · Poland (4) · South Korea (4)
Robert J. Motzer, MD (2) · Sumanta K Pal (2) · Alex Chehrazi-Raffle, MD (1) · Alexander Starodub, MD (1) · Apostolia M Tsimberidou (1) · Brian Shuch (1) · Charles B Nguyen (1) · Christopher G Wood, MD, FACP (1) · Darren Feldman, MD (1) · David Hong, MD (1)
PMID 37146227, PMID 15210739, PMID 22078932, PMID 22692704, PMID 26304872, PMID 29562145, PMID 30658932, PMID 30951193, PMID 31427204, PMID 31633185, PMID 31992108, PMID 32034074, PMID 32661118, PMID 32789967, PMID 33246931, PMID 33604999, PMID 34750035, PMID 35228755, PMID 35383907, PMID 35383908, PMID 35442713, PMID 36048457, PMID 36064785, PMID 36464584, PMID 36549781, PMID 36595123, PMID 36948504, PMID 37403652, PMID 38280218, PMID 38942995, PMID 39060019, PMID 39884775, PMID 40580957, PMID 42507969, PMID 42847673
P30CA033572 (5), 2009 (1), 2014 (1), 2017 (1), 2019 (1), 2023 (1), 2025 (1), N01CM00038 (1), P30CA093373 (1), U10CA180821 (1), UG1CA189961 (1)